ABT 263
Tocris Bioscience, part of Bio-Techne | Catalog # 7680
High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor
Key Product Details
Description
High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor
Product Description
ABT 263 is a high affinity inhibitor of Bcl-2 family proteins (Ki values are 0.5 nM, <1 nM and <1 nM in Bcl-xL, Bcl-2 and Bcl-W respectively). ABT 263 induces G1/G0 phase arrest, apoptosis and autophagy in cancer cells in vitro (IC50 = 3.4 - 12 μM). In vivo, ABT 263 displays a synergistic antitumor effect with rituximab and Bortezomib (Cat. No. 7282), Docetaxel (Cat. No. 4056) and Erlotinib (Cat. No. 7194), and inhibits growth of SCLC xenografts when combined with (+)-JQ1 (Cat. No. 4499). ABT 263 also reduces inflammation and viral-induced senescence in SARS-CoV-2 infection in vivo, and clears senescent cells and rejuvenates aging stem cells. Orally bioavailable.Product Specifications
Molecular Weight
974.62
Formula
C47H55ClF3N5O6S3
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
CAS Number
923564-51-6
PubChem ID
24978538
InChI Key
JLYAXFNOILIKPP-KXQOOQHDSA-N
SMILES
C(C1=C(CCC(C)(C)C1)C2=CC=C(Cl)C=C2)N3CCN(CC3)C4=CC=C(C(NS(=O)(=O)C5=CC(S(C(F)(F)F)(=O)=O)=C(N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)C=C5)=O)C=C4
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 97.46 | 100 |
Preparing Stock Solutions
for ABT 263
The following data is based on the product molecular weight 974.62
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.03 mL | 5.13 mL | 10.26 mL |
| 5 mM | 0.21 mL | 1.03 mL | 2.05 mL |
| 10 mM | 0.10 mL | 0.51 mL | 1.03 mL |
| 50 mM | 0.02 mL | 0.10 mL | 0.21 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Chang Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat.Med. 2016 PMID: 26657143
- Lee Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 2021 PMID: 34517409
- Wang JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. Oncotarget 2017 PMID: 29156797
- Tse ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008 PMID: 18451170
- Chen The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol.Cancer Ther. 2011 PMID: 21914853
Product Specific Notices for ABT 263
For research use only
Loading...
Loading...
Loading...